We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Most tumor cells showed weak to moderate nuclear positivity.
Cancer tissues showed strong nuclear staining in most cases.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
TATA-box binding protein associated factor 1 (HGNC Symbol)
Entrez gene summary
Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is the basal transcription factor TFIID, which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes the largest subunit of TFIID. This subunit binds to core promoter sequences encompassing the transcription start site. It also binds to activators and other transcriptional regulators, and these interactions affect the rate of transcription initiation. This subunit contains two independent protein kinase domains at the N- and C-terminals, but also possesses acetyltransferase activity and can act as a ubiquitin-activating/conjugating enzyme. Mutations in this gene result in Dystonia 3, torsion, X-linked, a dystonia-parkinsonism disorder. Alternative splicing of this gene results in multiple transcript variants. This gene is part of a complex transcription unit (TAF1/DYT3), wherein some transcript variants share exons with TAF1 as well as additional downstream DYT3 exons. [provided by RefSeq, Oct 2013]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
TAF1-007
TAF1-008
TAF1-009
TAF1-017
TAF1-201
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Enzymes ENZYME proteins Transferases SPOCTOPUS predicted secreted proteins Predicted intracellular proteins Transcription factors Other all-alpha-helical DNA-binding domains Cancer-related genes Mutational cancer driver genes Disease related genes Potential drug targets Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000166 [nucleotide binding] GO:0000209 [protein polyubiquitination] GO:0000790 [nuclear chromatin] GO:0000979 [RNA polymerase II core promoter sequence-specific DNA binding] GO:0001075 [transcription factor activity, RNA polymerase II core promoter sequence-specific binding involved in preinitiation complex assembly] GO:0001129 [RNA polymerase II transcription factor activity, TBP-class protein binding, involved in preinitiation complex assembly] GO:0002039 [p53 binding] GO:0003677 [DNA binding] GO:0003713 [transcription coactivator activity] GO:0004402 [histone acetyltransferase activity] GO:0004674 [protein serine/threonine kinase activity] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005667 [transcription factor complex] GO:0005669 [transcription factor TFIID complex] GO:0005730 [nucleolus] GO:0006351 [transcription, DNA-templated] GO:0006352 [DNA-templated transcription, initiation] GO:0006355 [regulation of transcription, DNA-templated] GO:0006366 [transcription from RNA polymerase II promoter] GO:0006367 [transcription initiation from RNA polymerase II promoter] GO:0006368 [transcription elongation from RNA polymerase II promoter] GO:0006468 [protein phosphorylation] GO:0006974 [cellular response to DNA damage stimulus] GO:0007049 [cell cycle] GO:0008134 [transcription factor binding] GO:0008284 [positive regulation of cell proliferation] GO:0010629 [negative regulation of gene expression] GO:0010767 [regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage] GO:0016032 [viral process] GO:0016301 [kinase activity] GO:0016310 [phosphorylation] GO:0016573 [histone acetylation] GO:0016740 [transferase activity] GO:0016746 [transferase activity, transferring acyl groups] GO:0017025 [TBP-class protein binding] GO:0018105 [peptidyl-serine phosphorylation] GO:0018107 [peptidyl-threonine phosphorylation] GO:0030901 [midbrain development] GO:0032092 [positive regulation of protein binding] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034644 [cellular response to UV] GO:0036369 [transcription factor catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0043565 [sequence-specific DNA binding] GO:0044212 [transcription regulatory region DNA binding] GO:0045943 [positive regulation of transcription from RNA polymerase I promoter] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0046777 [protein autophosphorylation] GO:0046982 [protein heterodimerization activity] GO:0050821 [protein stabilization] GO:0051123 [RNA polymerase II transcriptional preinitiation complex assembly] GO:0060260 [regulation of transcription initiation from RNA polymerase II promoter] GO:0060261 [positive regulation of transcription initiation from RNA polymerase II promoter] GO:0061628 [H3K27me3 modified histone binding] GO:0061631 [ubiquitin conjugating enzyme activity] GO:0070577 [lysine-acetylated histone binding] GO:0071318 [cellular response to ATP] GO:0071339 [MLL1 complex] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1902806 [regulation of cell cycle G1/S phase transition] GO:1903026 [negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding] GO:1905524 [negative regulation of protein autoubiquitination] GO:2000059 [negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:2000825 [positive regulation of androgen receptor activity]
Enzymes ENZYME proteins Transferases SPOCTOPUS predicted secreted proteins Predicted intracellular proteins Transcription factors Other all-alpha-helical DNA-binding domains Cancer-related genes Mutational cancer driver genes Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000166 [nucleotide binding] GO:0000209 [protein polyubiquitination] GO:0000790 [nuclear chromatin] GO:0000979 [RNA polymerase II core promoter sequence-specific DNA binding] GO:0001075 [transcription factor activity, RNA polymerase II core promoter sequence-specific binding involved in preinitiation complex assembly] GO:0001129 [RNA polymerase II transcription factor activity, TBP-class protein binding, involved in preinitiation complex assembly] GO:0002039 [p53 binding] GO:0003677 [DNA binding] GO:0003713 [transcription coactivator activity] GO:0004402 [histone acetyltransferase activity] GO:0004674 [protein serine/threonine kinase activity] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005667 [transcription factor complex] GO:0005669 [transcription factor TFIID complex] GO:0005730 [nucleolus] GO:0006351 [transcription, DNA-templated] GO:0006352 [DNA-templated transcription, initiation] GO:0006355 [regulation of transcription, DNA-templated] GO:0006366 [transcription from RNA polymerase II promoter] GO:0006367 [transcription initiation from RNA polymerase II promoter] GO:0006368 [transcription elongation from RNA polymerase II promoter] GO:0006468 [protein phosphorylation] GO:0006974 [cellular response to DNA damage stimulus] GO:0007049 [cell cycle] GO:0008134 [transcription factor binding] GO:0008284 [positive regulation of cell proliferation] GO:0010629 [negative regulation of gene expression] GO:0010767 [regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage] GO:0016032 [viral process] GO:0016301 [kinase activity] GO:0016310 [phosphorylation] GO:0016573 [histone acetylation] GO:0016740 [transferase activity] GO:0016746 [transferase activity, transferring acyl groups] GO:0017025 [TBP-class protein binding] GO:0018105 [peptidyl-serine phosphorylation] GO:0018107 [peptidyl-threonine phosphorylation] GO:0030901 [midbrain development] GO:0032092 [positive regulation of protein binding] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034644 [cellular response to UV] GO:0036369 [transcription factor catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0043565 [sequence-specific DNA binding] GO:0044212 [transcription regulatory region DNA binding] GO:0045943 [positive regulation of transcription from RNA polymerase I promoter] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0046777 [protein autophosphorylation] GO:0046982 [protein heterodimerization activity] GO:0050821 [protein stabilization] GO:0051123 [RNA polymerase II transcriptional preinitiation complex assembly] GO:0060260 [regulation of transcription initiation from RNA polymerase II promoter] GO:0060261 [positive regulation of transcription initiation from RNA polymerase II promoter] GO:0061628 [H3K27me3 modified histone binding] GO:0061631 [ubiquitin conjugating enzyme activity] GO:0070577 [lysine-acetylated histone binding] GO:0071318 [cellular response to ATP] GO:0071339 [MLL1 complex] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1902806 [regulation of cell cycle G1/S phase transition] GO:1903026 [negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding] GO:1905524 [negative regulation of protein autoubiquitination] GO:2000059 [negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:2000825 [positive regulation of androgen receptor activity]
Enzymes ENZYME proteins Transferases SPOCTOPUS predicted secreted proteins Predicted intracellular proteins Transcription factors Other all-alpha-helical DNA-binding domains Cancer-related genes Mutational cancer driver genes Disease related genes Potential drug targets Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000166 [nucleotide binding] GO:0000209 [protein polyubiquitination] GO:0000790 [nuclear chromatin] GO:0000979 [RNA polymerase II core promoter sequence-specific DNA binding] GO:0001075 [transcription factor activity, RNA polymerase II core promoter sequence-specific binding involved in preinitiation complex assembly] GO:0001129 [RNA polymerase II transcription factor activity, TBP-class protein binding, involved in preinitiation complex assembly] GO:0002039 [p53 binding] GO:0003677 [DNA binding] GO:0003713 [transcription coactivator activity] GO:0004402 [histone acetyltransferase activity] GO:0004674 [protein serine/threonine kinase activity] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005667 [transcription factor complex] GO:0005669 [transcription factor TFIID complex] GO:0005730 [nucleolus] GO:0006351 [transcription, DNA-templated] GO:0006352 [DNA-templated transcription, initiation] GO:0006355 [regulation of transcription, DNA-templated] GO:0006366 [transcription from RNA polymerase II promoter] GO:0006367 [transcription initiation from RNA polymerase II promoter] GO:0006368 [transcription elongation from RNA polymerase II promoter] GO:0006468 [protein phosphorylation] GO:0006974 [cellular response to DNA damage stimulus] GO:0007049 [cell cycle] GO:0008134 [transcription factor binding] GO:0008284 [positive regulation of cell proliferation] GO:0010629 [negative regulation of gene expression] GO:0010767 [regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage] GO:0016032 [viral process] GO:0016301 [kinase activity] GO:0016310 [phosphorylation] GO:0016573 [histone acetylation] GO:0016740 [transferase activity] GO:0016746 [transferase activity, transferring acyl groups] GO:0017025 [TBP-class protein binding] GO:0018105 [peptidyl-serine phosphorylation] GO:0018107 [peptidyl-threonine phosphorylation] GO:0030901 [midbrain development] GO:0032092 [positive regulation of protein binding] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0034644 [cellular response to UV] GO:0036369 [transcription factor catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0043565 [sequence-specific DNA binding] GO:0044212 [transcription regulatory region DNA binding] GO:0045943 [positive regulation of transcription from RNA polymerase I promoter] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0046777 [protein autophosphorylation] GO:0046982 [protein heterodimerization activity] GO:0050821 [protein stabilization] GO:0051123 [RNA polymerase II transcriptional preinitiation complex assembly] GO:0060260 [regulation of transcription initiation from RNA polymerase II promoter] GO:0060261 [positive regulation of transcription initiation from RNA polymerase II promoter] GO:0061628 [H3K27me3 modified histone binding] GO:0061631 [ubiquitin conjugating enzyme activity] GO:0070577 [lysine-acetylated histone binding] GO:0071318 [cellular response to ATP] GO:0071339 [MLL1 complex] GO:1901796 [regulation of signal transduction by p53 class mediator] GO:1902806 [regulation of cell cycle G1/S phase transition] GO:1903026 [negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding] GO:1905524 [negative regulation of protein autoubiquitination] GO:2000059 [negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:2000825 [positive regulation of androgen receptor activity]
The Human Protein Atlas project is funded
MENU
